Impairment disability and handicap scales in multiple sclerosis

被引:2
作者
Arbizu-Urdiain, T [1 ]
Martínez-Yélamos, A [1 ]
Casado-Ruiz, V [1 ]
机构
[1] Ciudad Sanitaria & Univ Bellvitge, Unidad Esclerosis Multiple, E-08907 Lhospitalet De Llobregat, Spain
关键词
composite; EDSS; evaluation scale; multiple sclerosis; quality of life scale;
D O I
10.33588/rn.3511.2002383
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction and method. In recent years the need to create scales for measuring the dysfunction or impairment suffered by patients with multiple sclerosis has increased. The aim of the scales that measure neurological impairment is twofold: to homogenise the data from different series so that studies into the prognosis and natural history of the disease can be compared, and to measure the changes in the progress of the disease when a therapy has been established. Over the past few years a large number of scales have appeared that attempt to redress the shortcomings of the EDSS (Expanded Disability Status Scale). The latest of these, the MSF Composite, manages to overcome the statistical problems of the EDSS and enables significant differences between two groups to be detected when studying the effect of a treatment. Conclusions. In the coming years we will possibly witness a joint use of several of the scales described, and both the EDSS and the Composite will be employed together in the evaluation of patients in therapeutic protocols, perhaps together with a quality of life scale.
引用
收藏
页码:1081 / 1093
页数:13
相关论文
共 40 条
[11]  
FISK DJ, 1994, CLIN INFECT DIS, V18, P579
[12]   THE IMPACT OF FATIGUE ON PATIENTS WITH MULTIPLE-SCLEROSIS [J].
FISK, JD ;
PONTEFRACT, A ;
RITVO, PG ;
ARCHIBALD, CJ ;
MURRAY, TJ .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1994, 21 (01) :9-14
[13]  
FOG T, 1965, ACTA NEUROL SCAND, VS 41, P551
[14]   AN ASSESSMENT OF DISABILITY RATING-SCALES USED IN MULTIPLE-SCLEROSIS [J].
FRANCIS, DA ;
BAIN, P ;
SWAN, AV ;
HUGHES, RAC .
ARCHIVES OF NEUROLOGY, 1991, 48 (03) :299-301
[15]  
Hall K.M., 1993, Journal of Head Trauma Rehabilitation, V8, P60, DOI [10.1097/00001199-199308020-00008, DOI 10.1097/00001199-199308020-00008]
[16]  
Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11
[17]   INTENSIVE IMMUNOSUPPRESSION IN PROGRESSIVE MULTIPLE-SCLEROSIS - A RANDOMIZED, 3-ARM STUDY OF HIGH-DOSE INTRAVENOUS CYCLOPHOSPHAMIDE, PLASMA-EXCHANGE, AND ACTH [J].
HAUSER, SL ;
DAWSON, DM ;
LEHRICH, JR ;
BEAL, MF ;
KEVY, SV ;
PROPPER, RD ;
MILLS, JA ;
WEINER, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (04) :173-180
[18]   Evaluating neurological outcome measures: The bare essentials [J].
Hobart, JC ;
Lamping, DL ;
Thompson, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 60 (02) :127-130
[19]  
*INT FED MULT SCLE, 1984, ACTA NEUROL SCAND S, V101, pS169
[20]   Concurrent validity of the MS functional composite using MRI as a biological disease marker [J].
Kalkers, NF ;
Bergers, L ;
de Groot, V ;
Lazeron, RHC ;
van Walderveen, MAA ;
Uitdehaag, BMJ ;
Polman, CH ;
Barkhof, F .
NEUROLOGY, 2001, 56 (02) :215-219